Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
70.00    0.00 (0.00%)
Bid:
69.00
Ask:
71.00
Spread: 2.00 (2.899%)
Market Cap: £318.58m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Additional Listing

22 Mar 2011 10:11

RNS Number : 3828D
Avacta Group PLC
22 March 2011
 



 

 

22 March 2011

 

 

Avacta Group plc

 

Issues of Equity

 

Avacta Group plc (the "Company") announces that 28,500,000 ordinary shares of 0.1p each ("Ordinary Shares") have been issued at a price of 0.25p per share, pursuant to the exercise of share warrants. The warrants were granted during May 2006, prior to the reversal of Avacta Limited into the Company, then named Readybuy plc.

Application has been made for the 28,500,000 Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 23 March 2011.

The Company also announces that a further 500,000 Ordinary Shares have been issued at a price of 0.25p per share, pursuant to the exercise of share warrants similarly granted during May 2006. Application has also been made for these 500,000 Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 25 March 2011.

The total number of Ordinary Shares, with voting rights, in issue following the above two issues of shares will be 1,664,487,577.

 

 

Enquiries:

 

Avacta Group plc

Tel: 0844 414 0452

Alastair Smith, Chief Executive Officer

Tim Sykes, Chief Financial Officer

www.avacta.com

Broker

XCAP Securities Limited

John Grant/Karen Kelly/David Newton

Nominated Adviser

Grant Thornton Corporate Finance

Tel: 020 7101 7070

www.xcapgroup.com

 

Tel: 020 7383 5100

www.grantthornton.co.uk

Colin Aaronson/David Hignell

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
LISLLFIIVRIFFIL
Date   Source Headline
8th Apr 20221:57 pmRNSIssue of Equity and Total Voting Rights
8th Apr 20227:00 amRNSAffyXell partners with Biocytogen and KNTSC
7th Apr 20224:31 pmRNSIssue of Equity and Total Voting Rights
6th Apr 20227:00 amRNSPreliminary Results
30th Mar 20224:41 pmRNSSecond Price Monitoring Extn
30th Mar 20224:35 pmRNSPrice Monitoring Extension
30th Mar 20227:00 amRNSNotice of Results and Investor Presentation
29th Mar 20227:00 amRNSAVA6000 data poster presentation at AACR
21st Mar 20227:00 amRNSDirectorate Change
16th Mar 20227:00 amRNSVimian acquires Avacta’s Animal Health Division
14th Feb 20224:41 pmRNSSecond Price Monitoring Extn
14th Feb 20224:36 pmRNSPrice Monitoring Extension
7th Feb 20224:36 pmRNSPrice Monitoring Extension
3rd Feb 20225:26 pmRNSIssue of Equity and Total Voting Rights
3rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20224:35 pmRNSPrice Monitoring Extension
3rd Feb 20227:00 amRNSDose escalation in the phase I trial of AVA6000
31st Jan 20224:41 pmRNSSecond Price Monitoring Extn
31st Jan 20224:36 pmRNSPrice Monitoring Extension
18th Jan 20227:00 amRNSSecond pre|CISION Pro-drug Candidate Selected
12th Jan 20222:05 pmRNSSecond Price Monitoring Extn
12th Jan 20222:00 pmRNSPrice Monitoring Extension
10th Jan 20227:00 amRNSUpdate on AffiDX and detection of Omicron variant
4th Jan 202211:06 amRNSSecond Price Monitoring Extn
4th Jan 202211:01 amRNSPrice Monitoring Extension
22nd Dec 20214:26 pmRNSIssue of Equity and Total Voting Rights
22nd Dec 202111:05 amRNSSecond Price Monitoring Extn
22nd Dec 202111:00 amRNSPrice Monitoring Extension
22nd Dec 20217:00 amRNSAffiDX Receives CE Mark for Consumer Self-Testing
16th Dec 20217:00 amRNSIssue of Equity and Total Voting Rights
15th Dec 20217:00 amRNSAffiDx® lateral flow test detects Omicron variant
15th Dec 20217:00 amRNSChange of auditor
29th Nov 20217:00 amRNSFDA Approval of IND Application for AVA6000
18th Nov 20214:41 pmRNSSecond Price Monitoring Extn
18th Nov 20214:36 pmRNSPrice Monitoring Extension
2nd Nov 20217:00 amRNSUpdate on UK Availability of AffiDX Test
14th Oct 20214:36 pmRNSPrice Monitoring Extension
14th Oct 202112:36 pmRNSIssue of Equity and Total Voting Rights
30th Sep 20217:00 amRNSInterim Results for the Period Ended 30 June 2021
29th Sep 20217:00 amRNSDevelopment Milestone in LG Chem Partnership
9th Sep 20217:00 amRNSNotice of Results
2nd Sep 20217:00 amRNSAppointment of Chief Scientific Officer
25th Aug 20214:40 pmRNSSecond Price Monitoring Extn
25th Aug 20214:35 pmRNSPrice Monitoring Extension
18th Aug 20217:00 amRNSDirectorate Change
11th Aug 20217:00 amRNSFirst Patient Dosed in AVA6000 Phase 1 Trial
4th Aug 20217:00 amRNSUpdate on AffiDX Lateral Flow Test
14th Jul 20217:00 amRNSDiagnostics achieves ISO 13485 Certification
12th Jul 20214:41 pmRNSSecond Price Monitoring Extn
12th Jul 20214:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.